Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PHPhaseBio Pharmaceuticals, Inc. logo

PhaseBio Pharmaceuticals, Inc. (PHAS)

NASDAQ Global Market · Currency in USD
$0.07 ▲ +0.00 (+0.00%)
At close: Nov 2, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.07
Open
$0.08
Day's Range
$0.07 – $0.09
52 Week Range
$0.04 – $4.08
Volume
8,603,716
Avg. Volume
1,756,632
Market Cap
$0
Beta (5Y Monthly)
2.87
PE Ratio (TTM)
--
EPS (TTM)
-$0.00
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: PhaseBio Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
60
CEO
Jonathan Mow

PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor. This drug is presently in Phase III clinical trials, targeting patients who are experiencing severe, uncontrolled, or life-threatening bleeding events, or those requiring immediate surgical or invasive interventions.

Earnings

DateEst.Actual
Aug 12, 2022-$0.31-$0.34Miss
May 16, 2022-$0.66-$0.23Beat
Mar 24, 2022-$0.59-$0.90Miss
Nov 10, 2021-$0.61-$0.66Miss
Aug 12, 2021-$0.46-$0.60Miss
May 13, 2021-$0.73-$0.87Miss

Analyst view

Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on PHAS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.